



MaxVal, A Leader in the IP Solutions Industry, Publishes Advanced CRISPR-Cas9 Report

MaxVal's professional services division has published an interactive patent landscape report on CRISPR-Cas9.

LOS ALTOS, CALIFORNIA, UNITED STATES, November 7, 2018 /EINPresswire.com/ -- Silicon Valley-



My colleagues and I have been paying close attention to the data science community, and more specifically, the practice of data agnosticism."

Mark O'Donnell, Vice President of Research and Analytics at MaxVal

based intellectual property solutions leader, MaxVal, announces their latest [advanced publication on the genome editing system](#), CRISPR, which has become an extremely important tool in medical research. The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research. The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer's, cancer, and numerous autoimmune diseases are being explored by researchers.

MaxVal's CRISPR report is now available through [Patent](#)

[LiveScope™](#), an analysis and reporting service that provides clients with dynamic reports which extract actionable and predictive information. By leveraging data sciences best practices, MaxVal has constructed an interactive report that melds different yet related data sources into a comprehensive landscape, allowing the reader to dynamically explore relationships.

"My colleagues and I have been paying close attention to the data science community, and more specifically, the practice of data agnosticism," says Mark O'Donnell, Vice President of Research and Analytics at MaxVal. "While patents provide us with important insights, they are just a small piece of the overall puzzle when it comes to decision making. We try to be inclusive of all data that is available to us, including patents, clinical trials, standards, 510ks, 10ks, products, sentiments, and more. This report is invaluable to those practicing in or investing in the genomics technology space."

What sets MaxVal apart, aside from its novel report delivery methods, are its experienced professionals with expertise that spans multiple domains. The MaxVal team is accustomed to working with complicated data from disparate sources and generating outputs that are pleasing to clients.

"There is a lot of excitement in the research community on the promise of the CRISPR toolbox in genome editing and beyond," says Ganesh Venkatraman, Manager of Research and Analytics at MaxVal. "Our team has been following the groundbreaking publications, product development, and commercialization efforts related to CRISPR with great interest. Much like the CRISPR toolbox, the Patent LiveScope™ reports are surprisingly simple, versatile and customizable."

To download the patent landscape report, [please click here](#). To learn more about MaxVal's professional services, including Patent Livescope™, please visit maxval.com/patent-services or email Mark O'Donnell at mark@maxval.com.

About MaxVal Group:

MaxVal is a Silicon Valley-based IP solutions provider, known for its cutting-edge products and automated solutions. Since 2004, MaxVal has been providing technology-enabled solutions and expert services to IP professionals, enabling IP counsels and their operations teams to increase efficiencies, scalability and quality.

Caitlyn Tuzzolino, Marketing Director
MaxVal Group, Inc.
650-472-0644
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.